Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 8, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-08

Reporting Person: Axon Steven (Chief Business Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$2.59	2027-05-17	Common Stock (398499)		Direct

Footnotes

F1: This option was granted on May 18, 2017 and will vest as to 25% of the shares underlying the options on January 1, 2018, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through January 1, 2021, subject to continued service.